A Phase II, Randomized, open-label study to evaluate low-dose Pembrolizumab plus Chemotherapy vs Chemotherapy as Neoadjuvant Therapy for localized Triple Negative Breast Cancer (TNBC). [PLANeT Trial - Pembrolizumab Low Dose in Addition to NACT in TNBC]
{{output}}
Background: Addition of pembrolizumab to neoadjuvant chemotherapy (NACT) is a standard of care treatment in non-metastatic triple negative breast cancer (TNBC). Trials employing reduced doses of immune checkpoint inhibitors have ... ...
